Merck, via one of its subsidiaries, will acquire CN201, an innovative investigational bispecific antibody currently in the clinical trial phase for treating B-cell related disorders.
TG Therapeutics, has obtained clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) Application to study Azercabtagene Zapreleucel (azer-cel).
ARS Pharmaceuticals has recently achieved a milestone with the U.S. Food and Drug Administration (FDA) approval of neffy® (epinephrine nasal spray) 2 mg.
Novartis gets FDA fast-track approval for Fabhalta® (iptacopan), marking it as the inaugural complement inhibitor to lower proteinuria in primary IgA nephropathy (IgAN).